Vnitr Lek 2013, 59(4):322-324

Use of vildagliptin from an internal disease specialist's point of view

R. Kožnarová
Centrum diabetologie, Klinika diabetologie, Institut klinické a experimentální medicíny, Praha, přednosta: prof. MUDr. Terezie Pelikánová, DrSc.

Dipeptidyl peptidase 4 inhibitors (DPP-4) are used as an oral hypoglycaemic agent in Type-2 diabetic patients. From a clinical point of view the most important advantages of this preparation are improved diabetes compensation, significant reduction of hypoglycaemia risk compared with sulfonylurea derivatives, neutral weight profile and good GIT tolerance. Vildagliptin is a molecule from the group of DPP-4 inhibitors which is recently used in internal outpatient care.

Keywords: diabetes mellitus; hypoglycaemia; safety; vildagiptin

Published: April 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kožnarová R. Use of vildagliptin from an internal disease specialist's point of view. Vnitr Lek. 2013;59(4):322-324.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Holman RR., Paul SK, Bethel MA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-89. Go to original source... Go to PubMed...
    2. Skyler JS, Bergenstal R, Bonow RO. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. Journal of the American College of Cardiology 2009; 53: 298-304. Go to original source... Go to PubMed...
    3. Drucker DJ, Sherman SI, Gorelick FS. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diab Care 2010; 33: 428-33. Go to original source... Go to PubMed...
    4. Haluzík M, Svačina Š. Inkretinová léčba diabetu. Praha: Mladá Fronta 2010.
    5. Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 2011; 13: 7-18. Go to original source... Go to PubMed...
    6. Kožnarová R. Vildagliptin - nový DPP-4 inhibitor. Postrgrad Med 2009; 11(7): 356-358.
    7. Šmahelová A, Slíva J. Vildagliptin. Farmakoterapie 2009; 1: 29-33.
    8. Kožnarová R., Slíva J. Vildagiptin/metformin, fixní léková kombinace. Farmakoterapie 2010; 6(1): 61-65.
    9. Abu-Hamdah R, Rabiee A, Meneilly GS. Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocr Metab 2009; 94: 1843-52. Go to original source... Go to PubMed...
    10. Ahren B, Pacini G, Tura A, Foley JE, Schweizer A. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes. Horm Metab Res 2007; 39:826-829. Go to original source... Go to PubMed...
    11. Vella A, Bock G, Giesler PD et al. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes 2007; 56:1475-1480 Go to original source... Go to PubMed...
    12. Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs 2011; 71: 1441-67. Go to original source... Go to PubMed...
    13. Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 2010;12(8):648-658. Review. Go to original source... Go to PubMed...
    14. Richard KR, Shelburne JS, Kirk JK. Tolerability of dipeptidyl peptidase-4 inhibitors: a review. Clin Ther 2011; 33(11):1609-1629. Go to original source... Go to PubMed...
    15. Mari A, Sallas WM, He YL. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005; 90:4888-4894. Go to original source... Go to PubMed...
    16. Matthews DR, Dejager S, Ahren B, Fonseca V, Ferrannini E, Couturier A, Foley JE, Zinman B. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab. 2010 Sep;12(9):780-9. Go to original source... Go to PubMed...
    17. Schweizer A. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes Obes Metab. 2010;12(6):485-494. Go to original source... Go to PubMed...
    18. Kvapil M. Porovnání klinické účinnosti inhibitorů DPP 4 sitagliptinu a vildagliptinu. Remedia 2009; 19(4): 273-279.
    19. Keating GM. Vildagliptin: a review of its use in type 2 diabetes mellitus. Drugs 2010; 70(16):2089-2112. Go to original source... Go to PubMed...
    20. Kothny W, Foley J, Kozlovski P, Shao Q, Gallwitz B, Lukashevich V. Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2013; 15(3):252-7. Go to original source... Go to PubMed...
    21. Haluzík M. Zkušenosti s vildagliptinem v terapii pacientů s diabetes mellitus 2. typu. Farmakoterapie 2012; 8(4): 426-430.
    22. Marfella R, Barbieri M, Grella R. Effects of vildagliptin twice daily v.s. sitagliptin once daily on 24-hour acute glucose fluctuation. J Diabetes Complications 2010; 24: 79-83. Go to original source... Go to PubMed...
    23. Monnier L, Colette C, Owens DR. Glyceamic variability: the third component of the dysglycemia in diabetes. Is it important? How to measure it? J Diab Sci Technol 2008; 2: 1094-1100. Go to original source... Go to PubMed...
    24. Kothny W, Shao Q, Groop PH, Lukashevich V. One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment. Diabetes Obes Metab. 2012; 14(11):1032-9. Go to original source... Go to PubMed...
    25. Ligueros-Saylan M, Foley J, Schweizer A, Couturier A, Kothny W. An assessment of adverse effects of vildagliptin versus comparators on the liver, the pankreas, the immune system, the skin and in patiens with impaired renal function from a large pooled database of Phase II a III clinical trials.Diabetes Obes Metab 2010;12: 495-509. Go to original source... Go to PubMed...
    26. Lukashevich V, Schweizer A, Shao Q, Groop PH, Kothny W. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diab Obes Metab. 201; 13(10):947-54.
    27. Pratley RE. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diab Care,2007; 30(12): 3017-22. Go to original source... Go to PubMed...
    28. Svačina Š. Vildagliptin/metformin - fixní kombinace. Remedia 2009; 19: 111-114.
    29. He YL, Flannery B, Campestrini J. Effect of food on the pharmacokinetics of a vildagliptin/metformin (50/1000 mg) fixed-dose combination tablet in healthy volunteers. Curr Med Res Opin 2008; 24:1703-1709. Go to original source... Go to PubMed...
    30. Schweizer A, Dejager S, Foley JE. Impact of insulin resistance, body mass index, disease duration, and duration of metformin use on the efficacy of vildagliptin. Diabetes Ther 2012; 3(1):8. Epub 2012 Jun 27. Go to original source... Go to PubMed...
    31. Inzucchi SE, Bergenstal RM, Buse JB. Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diab Care 2012; 35: 1364-79. Go to original source... Go to PubMed...
    32. Foley JE, Bunck MC, Möller-Goede DL, Poelma M, Nijpels G, Eekhoff EM, Schweizer A, Heine RJ, Diamant M. Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild. Diabetologia. 2011; 54(8):1985-1991. Go to original source... Go to PubMed...
    33. Schweizer A. Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naive patients with Type 2 diabetes. Diabet Med 2007; 955-961. Go to original source... Go to PubMed...
    34. Van Poppel PC et al. Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes. Diab Care. 2011;34(9):2072-7. Go to original source... Go to PubMed...
    35. Fonseca VA. Ongoing clinical trials evaluating the cardiovascular safety and efficacy of therapeutic approaches to diabetes mellitus. The Amer J of Cardiol 2011; 108: 52B-8B. Go to original source... Go to PubMed...
    36. Duttaroy A, Voelker F, Zhang X. The DPP-4 inhibitor vildagliptin increases b-cell mass in rodents. Diabetologia 2005; 48.

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.